Clinical trials: Eye Movement Disorder
Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia
A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders
This is a Phase II, randomized, placebo-controlled, double-blind, crossover study on the CNS and pharmacodynamic effects of clenbuterol (CST-103) co-administered with nadolol (CST-107) in 4 subject populations with…
- Trial name
- CLIN-011 (NCT04739423)
- Where
- 7 sites in Australia, New Zealand and 1 more
- Volunteers
- 41 people
- Sponsor
- CuraSen Therapeutics, Inc.
Autism, Autism Spectrum Disorder
Online Evaluation of the Diagnostic Accuracy of BlinkLab's Digital Assessments for Autism
This observational study aims to evaluate how patterns of behavioral and sensorimotor responses measured using the BlinkLab Dx1 smartphone application relate to autism diagnoses in children ages 2 to 11.
- Conditions
- Autism, Autism Spectrum Disorder, Autism Spectrum Disorder (ASD), Neurodevelopmental Conditions
- Trial name
- NCT07590973
- Testing
- BlinkLab Dx1, Retrospective Neurodevelopmental Diagnostic Assessment
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Blinklab Limited
Posttraumatic Stress Disorder (PTSD), Borderline Personality Disorder (BPD)
Effectiveness of PTSD-treatment Compared to Integrated PTSD-PD-treatment in Adult Patients With Comorbid PTSD and BPD
The goal of PROSPER-B is to study effectiveness of EMDR compared to integrated DBT-EMDR in treatment-seeking, adult patients with comorbid PTSD and Borderline Personality Disorder (BPD).
- Trial name
- PROSPER-B (NCT03833453)
- Testing
- EMDR, DBT
- Where
- Netherlands
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Arkin
PolG, Primary Mitochondrial Myopathy
Mitochondrial Video Assessment Source Material Study
Source material collection of videos to develop the Mitochondrial Video Assessment (MVA) for patients with mitochondrial myopathies.
- Trial name
- NCT06180421
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- The Emmes Company, LLC
Mitochondrial Diseases
A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease
A long-term extension study to assess the safety, tolerability and efficacy of cysteamine bitartrate delayed-release capsules (RP103) in children with inherited mitochondrial diseases who previously enrolled into study…
- Trial name
- NCT02473445
- Testing
- Cysteamine Bitartrate
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Amgen
Binocular Vision Disorder, Convergence Insufficiency
Neurolens Convergence Insufficiency Study
To understand the benefits of the neurolens Measurement Device and neurolens treatment as it pertains to treating symptoms related to Convergence Insufficiency.
- Conditions
- Binocular Vision Disorder, Convergence Insufficiency, Computer Vision Syndrome
- Trial name
- NCT05087563
- Testing
- Neurolens spectacle lens
- Where
- 9 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Neurolens Inc.
Progressive Supranuclear Palsy
A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy
The purpose of the study is to assess the long-term safety and tolerability of UCB0107 in study participants with progressive supranuclear palsy (PSP).
- Trial name
- NCT04658199
- Testing
- UCB0107 (bepranemab)
- Where
- 11 sites in Belgium, Germany and 2 more
- Volunteers
- 19 people
- Sponsor
- UCB Biopharma SRL
Progressive Supranuclear Palsy(PSP), Dementia With Lewy Bodies (DLB)
Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies
Progressive supranuclear palsy (PSP), mild cognitive impairment with Lewy bodies (MCI-LB), and Dementia with Lewy Bodies (DLB) are severe neurodegenerative diseases that cause significant motor impairment impacting daily…
- Conditions
- Progressive Supranuclear Palsy(PSP), Dementia With Lewy Bodies (DLB), PSP, Lewy Body Dementia (LBD)
- Trial name
- NCT07240805
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- BioSensics
Progressive Supranuclear Palsy
Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy
The purpose of this study is to determine wether NP031112 is safe and effective in the treatment of mild to moderate Progressive Supranuclear Palsy
- Trial name
- Tauros (NCT01049399)
- Testing
- tideglusib
- Where
- 24 sites in United States, Germany and 2 more
- Volunteers
- 146 people
- Sponsor
- Noscira SA
Progressive Supranuclear Palsy
GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)
The study will be conducted by the Sponsor to evaluate the efficacy and safety of GV1001 (0.56 mg and 1.12 mg) administered subcutaneously as a treatment for Progressive Supranuclear Palsy, (PSP).
- Trial name
- NCT05819658
- Testing
- GV1001 0.56mg, GV1001 1.12mg
- Where
- 5 sites in South Korea
- Volunteers
- 78 people
- Sponsor
- GemVax & Kael
Binocular Vision Disorder, Binocular Eye Movement Disorder
Performance and Safety Evaluation of the S360 Medical Device Software.
The aim of this interventional, cross-sectional study is to evaluate the performance and the safety of the medical device software S360.
- Conditions
- Binocular Vision Disorder, Binocular Eye Movement Disorder, Ocular Motion; Disorder
- Trial name
- ArgoS360 (NCT05522595)
- Testing
- S360
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Sierra Neurovision
Supranuclear Palsy, Progressive
Study of BIIB092 in Participants With Progressive Supranuclear Palsy
The Primary objective of the study is to evaluate the efficacy of BIIB092, compared to placebo, as measured by a change from baseline in the PSP Rating Scale (PSPRS) at Week 52 and to assess the safety and tolerability of…
- Trial name
- PASSPORT (NCT03068468)
- Testing
- BIIB092
- Where
- 86 sites in United States, Australia and 11 more
- Volunteers
- 490 people
- Sponsor
- Biogen
Brain Concussion, Cerebral Concussion
Use of Eye Movement Tracking to Detect Oculomotor Abnormality in Traumatic Brain Injury Patients
The purpose of this study is to determine the sensitivity and specificity of an aid in assessment of concussion based on eye-tracking, in comparison to a clinical reference standard appropriate for the Emergency Department (ED)…
- Conditions
- Brain Concussion, Cerebral Concussion, Concussion, Intermediate, Concussion, Mild
- Trial name
- DETECT (NCT02776462)
- Testing
- EyeBox CNS
- Where
- 2 sites in United States
- Volunteers
- 321 people
- Sponsor
- Oculogica, Inc.
Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
This is a sub-study of Study RM-493-040 (NCT05774756). The goal of this sub-study is to learn how well Setmelanotide works to improve weight reduction, hunger, and quality of life in patients 4 years of age and older with…
- Conditions
- Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia, Optic Nerve Hypoplasia
- Trial name
- NCT06760546
- Testing
- Setmelanotide
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 39 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Progressive Supranuclear Palsy
Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy
The purpose of the study is to evaluate the safety and efficacy of davunetide for the treatment of Progressive Supranuclear Palsy.
- Trial name
- NCT01110720
- Testing
- Davunetide
- Where
- 48 sites in United States, Australia and 4 more
- Volunteers
- 313 people
- Sponsor
- Allon Therapeutics
Mitochondrial Myopathies, Mitochondrial Pathology
Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)
SPIMD-301 is a 48-week, randomized, double-blind, parallel-group, placebo-controlled trial to assess efficacy and safety of single daily subcutaneous (SC) administration of elamipretide as a treatment for subjects with primary…
- Conditions
- Mitochondrial Myopathies, Mitochondrial Pathology, Mitochondrial DNA Mutation, Mitochondrial Diseases
- Trial name
- NuPower (NCT05162768)
- Testing
- Elamipretide
- Where
- 32 sites in United States, Australia and 8 more
- Volunteers
- 102 people
- Sponsor
- Stealth BioTherapeutics Inc.
Neurological Disorders
Development and Validation of a Novel Functional Eye-Tracking Software Application for Neurological Disorders
This study aims to develop and validate a sensitive and non-invasive eye-tracking software application. This study will obtain participant responses to brief cognitive tests designed to evaluate several key functions known to be…
- Trial name
- NCT05212727
- Testing
- Eye-tracking
- Where
- Canada
- Volunteers
- 300 people
- Sponsor
- Innodem Neurosciences
Nystagmus, Congenital Idiopathic, Nystagmus, Acquired
Efficacy and Safety Study of Neramexane to Treat Congenital and Acquired Nystagmus
The purpose of this study is to investigate the safety and efficacy of neramexane mesylate in the treatment of congenital idiopathic nystagmus (CIN) in comparison to placebo.
- Trial name
- NCT00661440
- Testing
- Neramexane mesylate
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- Merz Pharmaceuticals GmbH
Astigmatism
Effect of Eye Movement on Toric Lens Orientation and Visual Acuity
The relative performance of a new toric soft contact lens against toric contact lenses currently available in market, specifically for visual acuity and lens orientation.
- Trial name
- NCT00584831
- Testing
- senofilcon A, balafilcon A, omafilcon A
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Johnson & Johnson Vision Care, Inc.
Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
The KHENEREXT Study
This is an open-label, multi-centre study in subjects with a genetically confirmed mitochondrial deoxyribonucleic acid (DNA) transfer ribonucleic acid (tRNA)Leu(UUR) m.3243A>G mutation who completed study KH176-202.
- Conditions
- Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation, Maternally Inherited Diabetes and Deafness (MIDD), Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke Like Episodes (MELAS)
- Trial name
- NCT04604548
- Testing
- Oral administration of 100 mg KH176 twice daily
- Where
- 4 sites in Denmark, Germany and 2 more
- Volunteers
- 11 people
- Sponsor
- Khondrion BV